title: Ten developments in the use of biologicals for systemic lupus erythematosus.
abstract: Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.
authors.affiliation: Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. dwallace@ucla.edu
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Wallace
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D001691:Biological Therapy / Q000639:trends*; D002986:Clinical Trials as Topic / Q000379:methods; D017277:Drug Approval / Q000379:methods; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D017410:Practice Guidelines as Topic; D012107:Research Design
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; C511911:belimumab